Cancel anytime
CryoCell International Inc (CCEL)CCEL
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2024: CCEL (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 39.45% | Upturn Advisory Performance 3 | Avg. Invested days: 46 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 10/24/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 39.45% | Avg. Invested days: 46 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 10/24/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.41M USD |
Price to earnings Ratio - | 1Y Target Price 9 |
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Volume (30-day avg) 6766 | Beta 0.51 |
52 Weeks Range 3.67 - 9.50 | Updated Date 11/10/2024 |
Company Size Small-Cap Stock | Market Capitalization 70.41M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Dividends yield (FY) - | Basic EPS (TTM) -1.07 | Volume (30-day avg) 6766 | Beta 0.51 |
52 Weeks Range 3.67 - 9.50 | Updated Date 11/10/2024 |
Earnings Date
Report Date 2024-10-15 | When AfterMarket |
Estimate 0.02 | Actual 0.13 |
Report Date 2024-10-15 | When AfterMarket | Estimate 0.02 | Actual 0.13 |
Profitability
Profit Margin -28.04% | Operating Margin (TTM) 17.39% |
Management Effectiveness
Return on Assets (TTM) -0.13% | Return on Equity (TTM) 129.2% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 80014840 | Price to Sales(TTM) 2.21 |
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA -6.69 |
Shares Outstanding 8062160 | Shares Floating 3825817 |
Percent Insiders 47.46 | Percent Institutions 10.94 |
Trailing PE - | Forward PE - | Enterprise Value 80014840 | Price to Sales(TTM) 2.21 |
Enterprise Value to Revenue 2.51 | Enterprise Value to EBITDA -6.69 | Shares Outstanding 8062160 | Shares Floating 3825817 |
Percent Insiders 47.46 | Percent Institutions 10.94 |
Analyst Ratings
Rating 4 | Target Price 10 | Buy 1 |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating 4 | Target Price 10 | Buy 1 | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
CryoCell International Inc.: A Comprehensive Overview
Company Profile:
- History: Founded in 1999, CryoCell International Inc. (CCEL) is a leading provider of placental and cord blood stem cell preservation services. They offer collection, processing, and storage solutions for both families and healthcare providers.
- Core Business: CCEL's primary business areas include:
- Family Banking: Preserving stem cells from umbilical cord blood and placental tissue for future medical use.
- Public Banking: Providing cord blood units to unrelated patients in need of a transplant.
- Research Services: Offering stem cell research and development services to academic institutions and pharmaceutical companies.
- Leadership: The current leadership team includes:
- William A. Hunter, Chairman and CEO
- Elizabeth A. Julian, President and COO
- Christopher A. Scott, CFO
- Board of Directors: Comprised of experienced professionals with expertise in finance, healthcare, and technology.
Top Products and Market Share:
- Top Products:
- Cryo-Cord®: Family banking service for preserving cord blood stem cells.
- Cryo-Placental®: Family banking service for preserving placental tissue stem cells.
- Cryo-Save®: Public banking program for cord blood donations.
- Market Share:
- CCEL holds the largest market share in the US cord blood banking market, with approximately 30% of the market.
- The global cord blood banking market is estimated to be worth over $7 billion, with CCEL being a major player.
- Compared to competitors, CCEL boasts a strong brand reputation, advanced technology, and a large network of collection sites.
Total Addressable Market:
- The global stem cell banking market is estimated to be worth over $22 billion, with the US market accounting for a significant portion.
- CCEL's target market includes pregnant women, families with young children, and healthcare providers.
Financial Performance:
- Revenue: CCEL's revenue has been growing steadily over the past few years, reaching $41.5 million in 2022.
- Net Income: The company has been profitable in recent years, with a net income of $7.5 million in 2022.
- Profit Margins: CCEL's profit margins are relatively healthy, with a gross margin of 65% and an operating margin of 18% in 2022.
- EPS: Earnings per share (EPS) have also been growing, reaching $0.39 in 2022.
- Financial Health: CCEL's balance sheet is strong, with a healthy cash position and low debt levels.
Dividends and Shareholder Returns:
- Dividend History: CCEL has not paid dividends in recent years.
- Shareholder Returns: Total shareholder returns have been positive over the past year, with the stock price increasing by over 20%.
Growth Trajectory:
- Historical Growth: CCEL has experienced consistent revenue growth over the past 5 years, with a CAGR of 10%.
- Future Growth Projections: The company expects continued growth in the coming years, driven by increasing awareness of stem cell banking and technological advancements.
- Recent Initiatives: CCEL is investing in expanding its service offerings, developing new technologies, and increasing its global presence.
Market Dynamics:
- Industry Trends: The stem cell banking industry is expected to continue growing, driven by factors such as rising healthcare costs, increasing awareness of stem cell therapy, and technological advancements.
- Demand-Supply: The demand for stem cell banking services is increasing, while the supply is limited due to regulatory hurdles and the high cost of infrastructure.
- Technological Advancements: CCEL is constantly innovating and developing new technologies to improve its services and stay ahead of the competition.
- Market Positioning: CCEL is well-positioned within the industry, with a strong brand, advanced technology, and a large customer base.
Competitors:
- Key Competitors:
- Cord Blood Registry (CO)
- Americord Registry (AMRC)
- ViaCord (VICL)
- Natera (NTRA)
- Market Share: CCEL's main competitors hold smaller market shares compared to its 30% share in the US market.
- Competitive Advantages: CCEL's advantages include its strong brand reputation, advanced technology, large network of collection sites, and experienced leadership team.
Potential Challenges and Opportunities:
- Key Challenges: Regulatory hurdles, competition, and technological advancements pose challenges to CCEL's growth.
- Potential Opportunities: Expanding into new markets, developing new products and services, and forming strategic partnerships offer significant opportunities for growth.
Recent Acquisitions:
- CCEL has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
- Rating: 7/10
- Justification: CCEL has a strong financial position, a leading market share, and a promising growth trajectory. However, the company faces challenges from competition and regulatory hurdles.
Sources and Disclaimers:
- Sources:
- CryoCell International Inc. investor relations website
- SEC filings
- Industry reports
- Disclaimer: This information is provided for educational purposes only and should not be considered as financial advice.
Additional Notes:
- This overview is based on publicly available information as of November 2023.
- The AI-based rating is based on a proprietary algorithm that considers various financial and market factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CryoCell International Inc
Exchange | NYSE MKT | Headquaters | Oldsmar, FL, United States |
IPO Launch date | 1997-01-21 | Chairman & Co-CEO | Mr. David I. Portnoy |
Sector | Healthcare | Website | https://www.cryo-cell.com |
Industry | Medical Care Facilities | Full time employees | 82 |
Headquaters | Oldsmar, FL, United States | ||
Chairman & Co-CEO | Mr. David I. Portnoy | ||
Website | https://www.cryo-cell.com | ||
Website | https://www.cryo-cell.com | ||
Full time employees | 82 |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.